Drug:
Reaction: THERAPY INTERRUPTED
20250101 - 20251231
No. 301 - 400
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 301 | 25106587 |
60 | 2 | |
Vomiting, Diarrhoea, Gingival bleeding, Epistaxis, Therapy interrupted, |
||||
ABEMACICLIB, |
||||
| 302 | 25106643 |
US |
1 | |
Therapy interrupted, Illness, |
||||
APREMILAST, |
||||
| 303 | 25106859 |
81 | 2 | |
Pneumonia, White blood cell count decreased, Therapy interrupted, Muscle spasms, |
||||
LENALIDOMIDE, ALBUTEROL SULFATE, ALBUTEROL, ALLOPURINOL, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, CARVEDILOL, ERGOCALCIFEROL, DARATUMUMAB, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, APIXABAN, |
||||
| 304 | 25106866 |
US |
24 | 2 |
Rib fracture, Injury, Road traffic accident, Therapy interrupted, |
||||
CENEGERMIN-BKBJ, CARBOXYMETHYLCELLULOSE SODIUM, GLYCERIN, INSULIN LISPRO, INSULIN GLARGINE, ARTIFICIAL TEARS, LUBRICANT EYE DROPS, POLYVINYL ALCOHOL, POVIDONE, GLYCERIN, |
||||
| 305 | 25106887 |
2 | ||
Intestinal obstruction, Sleep disorder, Loss of personal independence in daily activities, Social problem, Therapy interrupted, |
||||
DORNASE ALFA, ALBUTEROL SULFATE, ALBUTEROL, AZELASTINE, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, FAMOTIDINE, GABAPENTIN, MONTELUKAST, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, |
||||
| 306 | 25106888 |
74 | 1 | |
Therapy interrupted, Circumstance or information capable of leading to medication error, |
||||
TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, |
||||
| 307 | 25107041 |
JP |
86 | 2 |
Cerebral infarction, Therapy interrupted, |
||||
ROMOSOZUMAB-AQQG, |
||||
| 308 | 25107161 |
GB |
1 | |
Fall, Malaise, Therapy interrupted, |
||||
CLOZAPINE, |
||||
| 309 | 25112320 |
|||
Illness, Therapy interrupted, |
||||
OCRELIZUMAB, |
||||
| 310 | 25112445 |
78 | 2 | |
Pyrexia, Fatigue, Pain in extremity, Gait disturbance, Blood sodium decreased, Blood magnesium decreased, Hypertransaminasaemia, Neutrophil count decreased, Nephrolithiasis, Hepatocellular injury, Infection, Hepatic ischaemia, Drug reaction with eosinophilia and systemic symptoms, Drug-induced liver injury, Immune-mediated hepatic disorder, Therapy interrupted, |
||||
TECLISTAMAB, |
||||
| 311 | 25112782 |
65 | 2 | |
Therapy interrupted, Hospitalisation, |
||||
CAPECITABINE, |
||||
| 312 | 25113129 |
72 | 2 | |
Illness, Therapy interrupted, |
||||
ETANERCEPT, ETANERCEPT, |
||||
| 313 | 25113255 |
63 | 2 | |
Oropharyngeal pain, Therapy interrupted, |
||||
ETANERCEPT, ETANERCEPT, |
||||
| 314 | 25113354 |
64 | 2 | |
Therapy interrupted, Infection, |
||||
ADALIMUMAB, |
||||
| 315 | 25113379 |
51 | 2 | |
Illness, Therapy interrupted, |
||||
ADALIMUMAB, ADALIMUMAB, |
||||
| 316 | 25113464 |
2 | ||
Thrombosis, Viral infection, Therapy interrupted, |
||||
ADALIMUMAB, |
||||
| 317 | 25113735 |
79 | 2 | |
Influenza, Therapy interrupted, Diarrhoea, |
||||
LENALIDOMIDE, |
||||
| 318 | 25113741 |
1 | ||
Cystitis, Therapy interrupted, |
||||
DAROLUTAMIDE, |
||||
| 319 | 25113773 |
2 | ||
Pneumonia, Therapy interrupted, |
||||
MACITENTAN, |
||||
| 320 | 25114104 |
56 | 2 | |
Fatigue, Visual impairment, Blood glucose increased, Therapy interrupted, |
||||
PALBOCICLIB, AMOXICILLIN, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, |
||||
| 321 | 25114399 |
80 | 2 | |
Therapy interrupted, Pneumonia, |
||||
TERIPARATIDE, |
||||
| 322 | 25114596 |
51 | 2 | |
COVID-19, Therapy interrupted, |
||||
ABATACEPT, |
||||
| 323 | 25097445 |
EG |
12 | 1 |
Expired device used, Wrong device used, Therapy interrupted, Device use issue, Product availability issue, Product substitution, Device mechanical issue, |
||||
SOMATROPIN, |
||||
| 324 | 25098201 |
US |
35 | 2 |
Psoriatic arthropathy, Insurance issue, Therapy interrupted, |
||||
CERTOLIZUMAB PEGOL, |
||||
| 325 | 25098210 |
US |
79 | 2 |
Hospitalisation, Dyspnoea, Urticaria, Therapy interrupted, Device issue, Drug dose omission by device, Incorrect dose administered, |
||||
AMIKACIN, AMIKACIN, |
||||
| 326 | 25098370 |
US |
2 | |
Mast cell activation syndrome, Loss of consciousness, Syncope, Illness, Autonomic nervous system imbalance, Brain fog, Bradycardia, Tachycardia, Therapy interrupted, Off label use, |
||||
IVABRADINE, IVABRADINE, IVABRADINE, IVABRADINE, PROPRANOLOL HYDROCHLORIDE, ATENOLOL, FAMOTIDINE, |
||||
| 327 | 25098415 |
GB |
||
Dehydration, Body temperature abnormal, Ill-defined disorder, Blood potassium decreased, Blood magnesium decreased, Abdominal symptom, Therapy interrupted, Intentional dose omission, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 328 | 25098418 |
CA |
56 | 1 |
Renal impairment, Abdominal discomfort, Abdominal pain, Infusion site pain, Infusion site erythema, Nausea, Headache, Musculoskeletal stiffness, Fatigue, Back pain, Dyspnoea, Malaise, Pollakiuria, Gait disturbance, Pain, Decreased appetite, Abdominal distension, Tremor, Chills, Influenza like illness, Muscle spasms, Off label use, Therapy interrupted, Suspected COVID-19, Nightmare, |
||||
DAPAGLIFLOZIN, RAMIPRIL, MOMETASONE, |
||||
| 329 | 25098481 |
US |
46 | 2 |
Pain, Therapy interrupted, |
||||
APREMILAST, |
||||
| 330 | 25098575 |
US |
2 | |
Influenza, Therapy interrupted, Underdose, |
||||
TROFINETIDE, |
||||
| 331 | 25098629 |
US |
||
Therapy interrupted, |
||||
ISOTRETINOIN, |
||||
| 332 | 25098631 |
US |
||
Therapy interrupted, |
||||
ISOTRETINOIN, |
||||
| 333 | 25098852 |
US |
69 | 2 |
Arthralgia, Therapy interrupted, |
||||
EVOLOCUMAB, |
||||
| 334 | 25098881 |
US |
1 | |
Product distribution issue, Therapy interrupted, Off label use, |
||||
LENALIDOMIDE, |
||||
| 335 | 25099013 |
GB |
2 | |
Schizophrenia, Therapy interrupted, |
||||
CLOZAPINE, |
||||
| 336 | 25099094 |
US |
72 | 2 |
Therapy interrupted, Product prescribing issue, Off label use, |
||||
LENALIDOMIDE, |
||||
| 337 | 25099243 |
US |
||
Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 338 | 25099445 |
US |
71 | 2 |
Fall, Haemoglobin abnormal, Blood pressure abnormal, COVID-19 pneumonia, Product availability issue, Dyspnoea, Therapy interrupted, |
||||
RIOCIGUAT, RIOCIGUAT, DUPILUMAB, |
||||
| 339 | 25099646 |
US |
70 | 1 |
Insurance issue, Malaise, Therapy interrupted, Product use issue, |
||||
ABATACEPT, |
||||
| 340 | 25099716 |
BR |
||
Colitis ulcerative, Malaise, Arthritis, Osteitis, Pain in extremity, Pruritus, Influenza, Arthralgia, Hypoaesthesia, Therapeutic response shortened, Intentional dose omission, Drug ineffective, Therapy interrupted, Intentional product use issue, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, LOSARTAN, QUETIAPINE, QUETIAPINE EXTENDED-RELEASE, CLONAZEPAM, TRAZODONE HYDROCHLORIDE, LITHIUM, LITHIUM BROMATUM, TRAZODONE HYDROCHLORIDE, |
||||
| 341 | 25099948 |
CA |
||
Hospitalisation, Therapy interrupted, |
||||
NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE, |
||||
| 342 | 25100630 |
2 | ||
Cardiac operation, Therapy interrupted, |
||||
ASCIMINIB, |
||||
| 343 | 25100631 |
|||
Hospitalisation, Therapy interrupted, |
||||
RISANKIZUMAB-RZAA, |
||||
| 344 | 25100692 |
62 | 2 | |
Acute kidney injury, Therapy interrupted, |
||||
VELPATASVIR AND SOFOSBUVIR, VELPATASVIR AND SOFOSBUVIR, |
||||
| 345 | 25101033 |
US |
76 | 2 |
Major depression, Carotid artery occlusion, Suicidal ideation, Cerebrovascular accident, Transient ischaemic attack, Apathy, Cardiac disorder, Low density lipoprotein increased, Drug ineffective, Sexual abuse, Arteritis, Hypertension, COVID-19, Inappropriate schedule of product administration, Therapy interrupted, Post-traumatic stress disorder, Memory impairment, Influenza, |
||||
EVOLOCUMAB, |
||||
| 346 | 25101037 |
44 | 2 | |
Pneumonia, Therapy interrupted, |
||||
ETANERCEPT, |
||||
| 347 | 25101302 |
48 | 2 | |
Altered state of consciousness, Somnolence, Heart rate increased, Blood pressure increased, Therapy interrupted, Unevaluable event, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, |
||||
| 348 | 25101560 |
US |
54 | 2 |
Product storage error, Therapy interrupted, |
||||
OZANIMOD HYDROCHLORIDE, |
||||
| 349 | 25101576 |
US |
1 | |
COVID-19, Insurance issue, Therapy interrupted, |
||||
CERTOLIZUMAB PEGOL, |
||||
| 350 | 25101729 |
US |
67 | 2 |
Product physical issue, Therapy interrupted, Nasopharyngitis, |
||||
LENALIDOMIDE, |
||||
| 351 | 25104315 |
26 | 2 | |
Posterior fossa decompression, Therapy interrupted, |
||||
ONABOTULINUMTOXINA, |
||||
| 352 | 25104366 |
51 | 2 | |
Illness, Therapy interrupted, |
||||
ETANERCEPT, |
||||
| 353 | 25104369 |
59 | 2 | |
Therapy interrupted, Influenza, |
||||
ETANERCEPT, |
||||
| 354 | 25104397 |
71 | 2 | |
Influenza, Pneumonia, Therapy interrupted, |
||||
ETANERCEPT, |
||||
| 355 | 25104477 |
75 | 2 | |
Infection, Therapy interrupted, |
||||
ADALIMUMAB, |
||||
| 356 | 25104560 |
72 | 2 | |
Hypertension, Therapy interrupted, Hypotension, |
||||
SONIDEGIB, |
||||
| 357 | 25104600 |
1 | ||
Influenza, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 358 | 25104631 |
79 | 2 | |
Infection, Therapy interrupted, |
||||
ABATACEPT, |
||||
| 359 | 25104638 |
13 | 1 | |
Neuropathy peripheral, Therapy interrupted, |
||||
METRONIDAZOLE, METRONIDAZOLE TOPICAL, |
||||
| 360 | 25104748 |
65 | 2 | |
Infection, Therapy interrupted, |
||||
UPADACITINIB, |
||||
| 361 | 25104752 |
60 | 2 | |
Infection, Therapy interrupted, |
||||
UPADACITINIB, UPADACITINIB, |
||||
| 362 | 25104990 |
71 | 1 | |
Fall, Haematemesis, Gastric ulcer haemorrhage, Red blood cell transfusion, Therapy interrupted, |
||||
APIXABAN, |
||||
| 363 | 25105112 |
53 | 1 | |
Cerebral artery occlusion, Cerebrovascular accident, Rectal haemorrhage, Therapy interrupted, |
||||
APIXABAN, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, |
||||
| 364 | 25105176 |
91 | 1 | |
Lower gastrointestinal haemorrhage, Anaemia, Red blood cell transfusion, Therapy interrupted, |
||||
APIXABAN, |
||||
| 365 | 25105285 |
78 | 1 | |
Pulmonary embolism, Therapy interrupted, |
||||
APIXABAN, |
||||
| 366 | 25106243 |
81 | 1 | |
Gastrointestinal haemorrhage, Rectal haemorrhage, Intestinal polyp, Therapy interrupted, Red blood cell transfusion, |
||||
APIXABAN, |
||||
| 367 | 25106259 |
68 | 1 | |
Therapy interrupted, Angioedema, |
||||
LISINOPRIL, |
||||
| 368 | 25092189 |
US |
79 | 2 |
Hip fracture, Therapy interrupted, Fall, |
||||
LENALIDOMIDE, |
||||
| 369 | 25092309 |
US |
||
Therapy interrupted, |
||||
BOSENTAN, |
||||
| 370 | 25092370 |
US |
2 | |
Thyroid disorder, Therapy interrupted, |
||||
CINACALCET HYDROCHLORIDE, |
||||
| 371 | 25092957 |
FR |
48 | 2 |
Constipation, Vomiting, Weight decreased, Infection, Therapy interrupted, Therapy non-responder, |
||||
PEMETREXED, PEMETREXED DISODIUM, PEMETREXED, PEMETREXED DISODIUM, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, PEMBROLIZUMAB, PEMBROLIZUMAB, CISPLATIN, METHYLPREDNISOLONE, |
||||
| 372 | 25092962 |
US |
40 | 2 |
Seizure, Device difficult to use, Therapy interrupted, |
||||
ERENUMAB-AOOE, ERENUMAB-AOOE, |
||||
| 373 | 25093396 |
US |
1 | |
Hospitalisation, Cardiac disorder, Cough, Productive cough, Therapy interrupted, |
||||
AMIKACIN, |
||||
| 374 | 25093592 |
US |
1 | |
Hospitalisation, Therapy interrupted, |
||||
AMIKACIN, |
||||
| 375 | 25093596 |
US |
2 | |
Pulmonary oedema, COVID-19 pneumonia, Pleural effusion, Hospitalisation, Pneumonia, Eye discharge, Eyelid margin crusting, Dry eye, Influenza, Condition aggravated, COVID-19, Throat irritation, Oropharyngeal pain, Oropharyngeal discomfort, Haemoptysis, Off label use, Therapy interrupted, |
||||
AMIKACIN, AMIKACIN, |
||||
| 376 | 25093600 |
CA |
83 | 2 |
Blood iron decreased, Dyspnoea, Dysuria, Fatigue, Lymphadenitis, Oxygen saturation decreased, Palpitations, Pallor, Patient dissatisfaction with treatment, Poor quality sleep, Therapy interrupted, Urinary retention, |
||||
METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, BRODALUMAB, BRODALUMAB, AMLODIPINE, |
||||
| 377 | 25093677 |
AU |
48 | 1 |
Hospitalisation, Therapy interrupted, |
||||
CLOZAPINE, CLOZAPINE, |
||||
| 378 | 25093712 |
US |
||
Therapy interrupted, |
||||
ISOTRETINOIN, ISOTRETINOIN, |
||||
| 379 | 25093714 |
US |
||
Therapy interrupted, |
||||
BOSENTAN, |
||||
| 380 | 25093837 |
US |
70 | 1 |
Product supply issue, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 381 | 25094150 |
US |
47 | 2 |
Fatigue, Asthenia, Condition aggravated, Ear infection, Respiratory tract congestion, Ear discomfort, Oropharyngeal pain, Aphonia, Hypoacusis, Balance disorder, Therapy interrupted, |
||||
AMIKACIN, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, |
||||
| 382 | 25094352 |
US |
||
Penile size reduced, Scrotal discomfort, Asthenia, Hot flush, Therapy interrupted, |
||||
RELUGOLIX, |
||||
| 383 | 25094577 |
US |
66 | 1 |
Diverticulitis, Peyronie^s disease, Skin disorder, Eye symptom, Neck pain, Head discomfort, Defaecation urgency, Gastrointestinal polyp, Sensitive skin, Unevaluable event, Skin discolouration, Fear of injection, Musculoskeletal discomfort, Therapy interrupted, Product dose omission in error, Abdominal discomfort, Pain, Dizziness, Injection site pain, Abdominal pain, Nausea, |
||||
ABALOPARATIDE, ABALOPARATIDE, MAGNESIUM, HYDROCHLOROTHIAZIDE, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, MONTELUKAST SODIUM, MONTELUKAST, GABAPENTIN, DIVALPROEX SODIUM, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, MELOXICAM, |
||||
| 384 | 25094741 |
US |
66 | 1 |
Therapy interrupted, |
||||
ADAGRASIB, |
||||
| 385 | 25094824 |
82 | 2 | |
Fall, Pelvic fracture, Therapy interrupted, Abdominal pain, Insomnia, Pain, Nausea, Vomiting, Productive cough, Hydronephrosis, Peritoneal neoplasm, Pancreatic disorder, Splenic vein occlusion, Hepatic lesion, |
||||
GEMCITABINE HYDROCHLORIDE, PACLITAXEL, |
||||
| 386 | 25095002 |
US |
||
Therapy interrupted, |
||||
GOLIMUMAB, |
||||
| 387 | 25095572 |
US |
93 | 2 |
Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 388 | 25095612 |
US |
61 | 2 |
Dysstasia, Monoparesis, Therapy interrupted, Therapy interrupted, Multiple sclerosis relapse, Gait disturbance, Product dose omission issue, |
||||
DALFAMPRIDINE, DALFAMPRIDINE, OXYBUTYNIN, BACLOFEN, GLATIRAMER ACETATE, |
||||
| 389 | 25095658 |
US |
1 | |
Peroneal nerve palsy, Therapy interrupted, |
||||
DALFAMPRIDINE, DALFAMPRIDINE, GABAPENTIN, |
||||
| 390 | 25095951 |
US |
61 | 1 |
Hospitalisation, Therapy interrupted, Inability to afford medication, |
||||
RIFAXIMIN, |
||||
| 391 | 25095974 |
US |
81 | 2 |
Therapy interrupted, |
||||
APREMILAST, |
||||
| 392 | 25096210 |
US |
77 | 1 |
Therapy interrupted, Inability to afford medication, |
||||
LENALIDOMIDE, |
||||
| 393 | 25096472 |
US |
38 | 2 |
Hysterectomy, Rheumatoid arthritis, Insurance issue, Therapy interrupted, |
||||
CERTOLIZUMAB PEGOL, |
||||
| 394 | 25097031 |
US |
||
Mood altered, Night sweats, Therapy interrupted, |
||||
RELUGOLIX, |
||||
| 395 | 25097033 |
US |
||
Hot flush, Therapy interrupted, |
||||
RELUGOLIX, AMLODIPINE, LISINOPRIL, HYDROCHLOROTHIAZIDE, |
||||
| 396 | 25099135 |
2 | ||
Haemorrhage, Therapy interrupted, |
||||
TADALAFIL, TREPROSTINIL, SOTATERCEPT-CSRK, AMBRISENTAN, |
||||
| 397 | 25099246 |
2 | ||
Therapy interrupted, |
||||
BEXAROTENE, ALPRAZOLAM, AMLODIPINE, CYCLOBENZAPRINE, DULOXETINE HYDROCHLORIDE, DULOXETINE, FENOFIBRATE, HYDROXYCHLOROQUINE, LEVOTHYROXINE, |
||||
| 398 | 25099415 |
2 | ||
Haemoglobin decreased, Therapy interrupted, |
||||
NIRAPARIB, |
||||
| 399 | 25099431 |
|||
Therapy interrupted, Behaviour disorder, |
||||
LISDEXAMFETAMINE, |
||||
| 400 | 25099487 |
2 | ||
Constipation, Therapy interrupted, |
||||
ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR, LUMACAFTOR AND IVACAFTOR, PANCRELIPASE, TOBRAMYCIN, TOBRAMYCIN SULFATE, TOBRAMYCIN SOLUTION, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28